

REMARKS

Claims 1-33 are pending in the above-identified application. With this Amendment, Claims 1-8 have been cancelled thereby leaving only Claims 9-33 for consideration. A complete listing of the claims and their status is attached hereto as Appendix A.

The specification has been amended to identify parent application Serial No. 09/163,646 and to include a claim of priority. A copy of the original Declaration and Power of Attorney is submitted herewith pursuant to M.P.E.P. 201.06(c).

Accordingly, Applicant respectfully requests prompt and favorable consideration by the Examiner of the now pending application.

Respectfully submitted,

Dated: September 10, 2003

By: _____



Lara Dickey Lewis
Registration No. 48,161
SONNENSCHN NATH & ROSENTHAL LLP
P.O. Box 061080
Wacker Drive Station, Sears Tower
Chicago, Illinois 60606-1080
(816) 460-2516

APPENDIX A

1. (Canceled)

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Canceled)

8. (Canceled)

9. (Original) In an implant adapted for subcutaneous implantation in an animal's ear by an implanter apparatus through the bore of a hypodermic needle which is coupled to a pellet magazine, the improvement comprising:

- (a) said implant including a plurality of pellets sized and shaped to be implanted through the needle and positioned in the magazine for selective alignment of the implant with the needle; and
- (b) the pellets of a single implant including both at least one immediate release parasiticide agent pellet dose and at least one extended release parasiticide agent pellet dose.

10. (Original) The implant according to Claim 9 wherein the pellets are packaged in the magazine in sequential order for delivery of an immediate release parasiticide agent dose in at least one discrete pellet followed by an extended release parasiticide agent dose in at least one pellet for subcutaneous placement in a single injection.

11. (Original) The implant according to Claim 10 wherein said immediate release and said extended release parasitocidal agent pellet doses separately comprise a parasitocidal agent selected from the group consisting of avermectins, milbemycins, milbemycin oximes, fenbendazoles, lufenarons, derivatives and mixtures thereof.

12. (Original) The implant according to Claim 11 wherein said parasitocidal agent comprises an avermectin selected from the group consisting of ivermectin, doramectin, moxidectin, eprinomectrin, abamectin, derivatives and mixtures thereof.

13. (Original) The implant according to Claim 10 wherein said immediate release parasitocidal agent pellet dose further comprises a disintegration agent and said extended release parasitocidal agent pellet dose further comprises a bioerodible matrix.

14. (Original) An implant for subcutaneous implantation in an animal's ear comprising:

- (a) at least one discrete immediate release parasitocidal agent pellet dose; and
- (b) at least one discrete extended release parasitocidal agent pellet dose, said pellet doses being combined in a single unit and being injectable into an animal at the same time for implantation side by side into the same site.

15. (Original) The implant according to Claim 14 further comprising an excipient and wherein each of said immediate release and said extended release parasitocidal agent pellet doses separately comprise a parasitocidal agent selected from the group consisting of the avermectins, milbemycins, milbemycin oximes, fenbendazoles, lufenarons, derivatives and mixtures thereof.

16. (Original) The implant according to Claim 15 wherein said parasitocidal agent comprises an avermectin selected from the group consisting of ivermectin, doramectin, moxidectin, eprinomectrin, abamectin, derivatives and mixtures thereof.

17. (Original) The implant according to Claim 14 wherein each immediate release parasitocidal agent pellet dose further comprises a disintegration agent and each extended release parasitocidal agent pellet dose further comprises a bioerodible matrix.

18. (Original) An implant adapted for subcutaneous implantation in an animal's ear comprising:

an immediate release pharmaceutical composition comprising at least one parasitocidal agent and a disintegration aid; and
an extended release pharmaceutical composition comprising at least one parasitocidal agent and a binding agent.

19. (Original) The implant of Claim 18, said parasitocidal agent being selected from the group consisting of avermectins, milbemycins, milbemycin oximes, fenbendazoles, lufenexons, derivatives and mixtures thereof.

20. (Original) The implant of Claim 19, said parasitocidal agent comprising an avermectin selected from the group consisting of ivermectin, doramectin, moxidectin, eprinomectrin, abamectin, derivatives and mixtures thereof.

21. (Original) The implant of Claim 18, said immediate release pharmaceutical composition comprising from about 25-125 mg of said parasitocidal agent.

22. (Original) The implant of Claim 18, said extended release pharmaceutical composition comprising from about 50-175 mg of said parasitocidal agent.

23. (Original) The implant of Claim 18, said disintegration aid being selected from the group consisting of magnesium stearate, croscarmellose sodium, microcrystalline cellulose, derivatives and mixtures thereof.

24. (Original) The implant of Claim 18, said binding agent being selected from the group consisting of lactose, polyethylene glycol, magnesium stearate, cellulose, ethylcellulose, polymeric supports, binders, coloring agents, derivatives and mixtures thereof.

25. (Original) The implant of Claim 18, said extended release pharmaceutical composition having a delivery period of at least 120 days.

26. (Original) A method for providing immediate and extended control of parasite infestation in an animal comprising the steps of:

- (a) providing an implant adapted for subcutaneous implantation in an animal's ear comprising an immediate release pharmaceutical composition comprising at least one parasitocidal agent and a disintegration aid, and an extended release pharmaceutical composition comprising at least one parasitocidal agent and a binding agent; and
- (b) implanting said implant into an animal's ear.

27. (Original) The method of Claim 26, said parasitocidal agent being selected from the group consisting of avermectins, milbemycins, milbemycin oximes, fenbendazoles, lufenexons, derivatives and mixtures thereof.

28. (Original) The method of Claim 27, said parasitocidal agent comprising an avermectin selected from the group consisting of ivermectin, doramectin, moxidectin, eprinomectrin, abamectin, derivatives and mixtures thereof.

29. (Original) The method of Claim 26, said immediate release pharmaceutical composition comprising from about 25-125 mg of said parasitocidal agent.

30. (Original) The method of Claim 26, said extended release pharmaceutical composition comprising from about 50-175 mg of said parasitocidal agent.

31. (Original) The method of Claim 26, said disintegration aid being selected from the group consisting of magnesium stearate, croscarmellose sodium, microcrystalline cellulose, derivatives and mixtures thereof.

32. (Original) The method of Claim 26, said binding agent being selected from the group consisting of lactose, polyethylene glycol, magnesium stearate, cellulose, ethylcellulose, polymeric supports, binders, coloring agents, derivatives and mixtures thereof.

33. (Original) The method of Claim 26, said extended release pharmaceutical composition having a delivery period of at least 120 days.